International Advocacy

Biotechnology helps societies solve old problems in new ways. Through the science of using living cells and the discovery of new molecules, biotech innovation provides societies with innovative means to address their most urgent needs: fighting disease, feeding the hungry, and improving the environment.

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

For companies looking to partner in China, they must first realize the unique needs of this market.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

BIO's President and CEO Jim Greenwood talks to BIO Ventures for Global Health (BVGH) CEO Don Joseph about global health and BVGH's new report on global health.

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

What does the future hold for the biotechnology industry in Japan? The Japanese government has made great strides to boost biotech within its borders.

Pavilions attract attendees and media alike, affording a space to tell your story within the context of a particular geographic region or specific focus area.

In this informative editorial Jim Greenwood, BIO President and CEO, presents an insight into China’s growing role in the future of biotechnology.

This week’s BIO China International Conference displayed a growing recognition of China’s emergence as a global leader in the biotech industry and discussions focused on how to navigate the opportunities and challenges that exist in the rapidly emerging market.

The buzz at BIO India hones in on the lack of clarity and consistency within the clinical trials process

During this period of tremendous growth in both the Indian economy and its healthcare sector, it is a critical time to capitalize on the biotech opportunities available within India.

With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing.

Letters, Testimony & Comments

June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.   
June 3 2013
BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products. Peru is a growing market for biotechnology products and with the implementation of the US-Peru TPA, it promises to become an even bigger market.
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of biological origin. Many elements of the third draft appear to have addressed BIO's previous comments with respect to clarity of structure and definitions of terms, as well as expectations for data requirements.   
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.

Press Releases

April 8 2013
Strong Intellectual Property Protection Is Vital For The Life Sciences Industry.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
April 5 2012
Centric Health Resources and the National Organization for Rare Disorders (NORD), Co-organizersAlnylam Pharmaceuticals, Genzyme, a Sanofi Company and Millennium: The Takeda Oncology Company, Co-sponsors
October 5 2011
BIO welcomed the transmission of the Korea-U.S. Free Trade Agreement (KORUS FTA) by President Obama to the Congress earlier this week.